Abstract: The invention relates to a cosmetic or dermatological composition, preferably purely plant-based, for topical use, containing Cimicifuga as the primary natural active ingredient, and to the use thereof for the prophylaxis and the treatment of skin diseases, in particular acne, seborrhea, atopic eczema (neurodermatitis), hirsutism, psoriasis, and dry/atopic skin of humans.

Abstract: The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or prophylaxis of post-menopausal urinary bladder infections. They are furthermore indicated for the treatment of benign and malignant prostate hyperplasies.

Abstract: The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or prophylaxis of post-menopausal urinary bladder infections. They are furthermore indicated for the treatment of benign and malignant prostate hyperplasies.

Abstract: The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or prophylaxis of post-menopausal urinary bladder infections. They are furthermore indicated for the treatment of benign and malignant prostate hyperplasies.

Abstract: The present invention relates to the use of extracts from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, atherosclerosis, osteoporosis and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.

Abstract: The present invention relates to the use of phytoestrogen-containing extracts that selectively modulate estrogen receptor beta (ER-beta) without producing any uterotropic effect, for the treatment of clinical situations and pathophysiological conditions that are selected from the group consisting of: Obesity and thereby to possibly influence the metabolic syndrome, particularly hypertension, asterosclerosis, cardiac infarct, hyperandrogenemia; Menopausal continence disorders; Menopausal heat surges associated with hyperstimulation of the hypothalamic gonadotropin releasing hormone pulse generator; steroid hormonal synthesis disorder, particularly that of progesterone synthesis of the human corpus luteum, resulting in luteal insuffeciency; Alzheimer's disease associated with elevated expression of estrogen receptor beta in hippocampal neurons.

Abstract: The present invention relates to the use of extracts from Iridaceae and from Cimicifuga racemosa, and of tectorigenin as an estrogen-type, organoselective medicament for the selective treatment and/or prophylaxis of cardiovascular diseases, in particular atherosclerose, osteoporose and climacteric disorders, e.g. for preventing or alleviating hot flushes. Uterotrophic effects are practically not observed.

Abstract: The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or prophylaxis of post-menopausal urinary bladder infections. They are furthermore indicated for the treatment of benign and malignant prostate hyperplasies.

Abstract: The present invention relates to extracts from the lridaceae plant Belamcanda chinensis for producing a ready-formulated medicament suited for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The inventive extracts are moreover suited for the treatment and/or prophylaxis of post-menopausal bladder infections and of urinary incontinence. The are moreover indicated for the treatment of benign and malignant prostate hyperplasies. It was moreover found that the ingredient tectorigenin as well as its glycosides, isolated from Belamcanda chinensis, essentially has the same effects as the whole extract.

Abstract: The present invention relates to a prolactin lowering drug containing at least one bicyclic diterpene of the labdane type.

Abstract: The present invention relates to a prolactin lowering drug containing at least one bicyclic diterpene of the labdane or clerodane type: wherein R1=H, C1 to C3 alkyl or C1 to C3 acyl.

Abstract: 3-Hydrazinoindazoles acylated with a carbo(lower alkoxy) group in the 3-position and further being optionally substituted in one or more of the 4-, 5-, 6- and/or 7-positions are analgesic, anti-inflammatory and antipyretic agents. The compounds, of which 3-carbomethoxyhydrazino-6-chloroindazole is a typical embodiment, are prepared through treatment of the appropriate 3-hydrazinoindazole with a derivative of carbonic acid.

Abstract: 3-Aminoindazoles bearing a carbo(lower alkoxy), lower alkylamide or di(lower alkyl)amide group in the 1-or 2-position and further being optionally substituted in one or more of the 4-, 5-, 6- and/or 7-positions are analgesic, anti-inflammatory and antipyretic agents. The compounds, of which 3-amino-6-chloroindazole-1-carboxylic acid ethyl ester is a typical embodiment, are prepared through treatment of the appropriate 3-aminoindazole with a derivative of carbonic acid or through thermal isomerization.